

Cover Story
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
By Alexandria Carolan
In Brief
Clinical Roundup
Drugs & Targets


Trending Stories
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Trump backs off the 100% pharma tariffs ultimatum